PA
SGMT icon

Parallel Advisors’s Sagimet Biosciences SGMT Stock Holding History

Parallel Advisors’s Portfolio SGMT Stock Details SGMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$4.44K Hold
849
– – ﹤0.01% 3078
2025
Q4 		$5.03K Buy
+849
New +$6.1K ﹤0.01% 2841

Other funds holding SGMT

VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Parallel Advisors's SGMT Position: Q1 2026 in Review

Parallel Advisors held its Sagimet Biosciences (SGMT) position steady in Q1 2026 at 849 shares worth $4.44K. The position accounts for ﹤0.01% of the portfolio, ranked #3078.

Parallel Advisors first reported a position in SGMT in Q4 2025 and has held it in 2 quarters since. The position peaked at $5.03K in Q4 2025. 88 funds tracked by Wall St. Rank hold SGMT as of Q1 2026.

  • Parallel Advisors held 849 shares of Sagimet Biosciences worth $4.44K as of Q1 2026.
  • Parallel Advisors left its Sagimet Biosciences share count unchanged in Q1 2026.
  • Sagimet Biosciences made up ﹤0.01% of Parallel Advisors's portfolio in Q1 2026, its #3078 holding.
  • Parallel Advisors first reported a position in Sagimet Biosciences in Q4 2025 and has held it in 2 quarters since.
  • Parallel Advisors's Sagimet Biosciences position peaked at $5.03K in Q4 2025.
  • 88 funds tracked by Wall St. Rank held Sagimet Biosciences as of Q1 2026.

Based on Parallel Advisors's 13F filing for Q1 2026, filed 7 May 2026.